Chatham Capital Group Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 51,543 shares of the company’s stock after acquiring an additional 1,182 shares during the period. Johnson & Johnson accounts for about 1.8% of Chatham Capital Group Inc.’s holdings, making the stock its 9th biggest position. Chatham Capital Group Inc.’s holdings in Johnson & Johnson were worth $8,531,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth $4,609,399,000. Providence Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 141,974.0% during the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock worth $30,651,000 after buying an additional 4,747,612 shares during the last quarter. Morgan Stanley increased its holdings in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. 68.40% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $160.50 on Monday. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The firm’s 50-day moving average price is $166.51 and its two-hundred day moving average price is $162.06. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04. The stock has a market capitalization of $417.13 billion, a P/E ratio of 32.49, a P/E/G ratio of 3.25 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter last year, the company posted $2.59 earnings per share. Johnson & Johnson’s revenue was up 6.3% on a year-over-year basis. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were issued a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Reasons This Sleeping Giant Is About To Wake Up
- How to Use Stock Screeners to Find Stocks
- MarketBeat Week in Review – 9/18 – 9/22
- Want to Profit on the Downtrend? Downtrends, Explained.
- 52-week Low Names To Tip The Upside Scale In Your Favor
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
